This prompted a paradigm shift toward the search for molecularly targeted agents against other putative driver aberrations in NSCLC and has led to the development of novel therapeutics matched against specific actionable aberrations, such as crizotinib (Pfizer) against ALK and ROS1 aberrations (6, 7) (Figure 1). This evidence concerns the gene ALK and non-small cell lung carcinoma.